UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

The preclinical pharmacology of roflumilast – A selective, oral phosphodiesterase 4 inhibitor in development for chronic obstructive pulmonary disease

Pulmonary pharmacology & therapeutics, 2010-08, Vol.23 (4), p.235-256

2010

Volltextzugriff (PDF)

cAMP Phosphodiesterase Inhibitors Increases Nitric Oxide Production by Modulating Dimethylarginine Dimethylaminohydrolases

Circulation (New York, N.Y.), 2011-03, Vol.123 (11), p.1194-1204

2011

Volltextzugriff (PDF)

Antiremodeling Effects of Iloprost and the Dual-Selective Phosphodiesterase 3/4 Inhibitor Tolafentrine in Chronic Experimental Pulmonary Hypertension

Circulation research, 2004-04, Vol.94 (8), p.1101-1108

2004

Volltextzugriff (PDF)

Phosphodiesterase 2 inhibition diminished acute lung injury in murine pneumococcal pneumonia

Critical care medicine, 2009-02, Vol.37 (2), p.584-590

2009

Volltextzugriff (PDF)

Inhaled tolafentrine reverses pulmonary vascular remodeling via inhibition of smooth muscle cell migration

Respiratory research, 2005-11, Vol.6 (1), p.128-128, Article 128

2005

Volltextzugriff (PDF)

Anti-inflammatory and immunomodulatory potential of the novel PDE4 inhibitor roflumilast in vitro

The Journal of pharmacology and experimental therapeutics, 2001-04, Vol.297 (1), p.267

2001

Volltextzugriff (PDF)

Phosphodiesterase Inhibitors

1, 1996

Volltextzugriff (PDF)

Effect of nitric oxide synthase (NOS) inhibition on macro- and microcirculation in a model of rat endotoxic shock

Thrombosis and haemostasis, 2006-04, Vol.95 (4), p.720-727

2006

Volltextzugriff (PDF)

Effects of theophylline and rolipram on leukotriene C4 (LTC4) synthesis and chemotaxis of human eosinophils from normal and atopic subjects

British journal of pharmacology, 1996-08, Vol.118 (7), p.1727-1735

1996

Volltextzugriff (PDF)

Detection of reactive oxygen species in isolated, perfused lungs by electron spin resonance spectroscopy

Respiratory research, 2005-07, Vol.6 (1), p.86-86, Article 86

2005

Volltextzugriff (PDF)

Low-dose systemic phosphodiesterase inhibitors amplify the pulmonary vasodilatory response to inhaled prostacyclin in experimental pulmonary hypertension

American journal of respiratory and critical care medicine, 1999-11, Vol.160 (5), p.1500-1506

1999

Volltextzugriff (PDF)

Smokers with COPD Show a Shift in Energy and Nitrogen Metabolism at Rest and During Exercise

International journal of chronic obstructive pulmonary disease, 2020-01, Vol.15, p.1-13

2020

Volltextzugriff (PDF)

Phosphodiesterase profiles of highly purified human peripheral blood leukocyte populations from normal and atopic individuals: A comparative study

Journal of allergy and clinical immunology, 1997-10, Vol.100 (4), p.527-535

1997

Volltextzugriff (PDF)

Subthreshold doses of specific phosphodiesterase type 3 and 4 inhibitors enhance the pulmonary vasodilatory response to nebulized prostacyclin with improvement in gas exchange

The Journal of pharmacology and experimental therapeutics, 2000-02, Vol.292 (2), p.512

2000

Volltextzugriff (PDF)

Characterization of the Phosphodiesterase (PDE) Pattern of in Vitro-Generated Human Dendritic Cells (DC) and the Influence of PDE Inhibitors on DC Function

Pulmonary pharmacology & therapeutics, 1999-12, Vol.12 (6), p.377-386

1999

Volltextzugriff (PDF)

Phosphodiesterase 1 upregulation in pulmonary arterial hypertension : Target for reverse-remodeling therapy

Circulation (New York, N.Y.), 2007-05, Vol.115 (17), p.2331-2339

2007

Volltextzugriff (PDF)

Protection from T cell-mediated murine liver failure by phosphodiesterase inhibitors

The Journal of pharmacology and experimental therapeutics, 1997-01, Vol.280 (1), p.53

1997

Volltextzugriff (PDF)

Tumor necrosis factor-α–dependent expression of phosphodiesterase 2: role in endothelial hyperpermeability

Blood, 2005-05, Vol.105 (9), p.3569-3576

2005

Volltextzugriff (PDF)

The specific type III and IV phosphodiesterase inhibitor zardaverine suppresses formation of tumor necrosis factor by macrophages

European journal of pharmacology, 1993-01, Vol.230 (1), p.9-14

1993

Volltextzugriff (PDF)

Phosphodiesterase inhibitors: history of pharmacology

Handbook of experimental pharmacology, 2011 (204), p.1

2011

Volltextzugriff (PDF)

Influence of selective phosphodiesterase inhibitors on human neutrophil functions and levels of cAMP and Cai

Naunyn-Schmiedeberg's archives of pharmacology, 1991-12, Vol.344 (6), p.682-690

1991

Volltextzugriff (PDF)

Phosphodiesterase 2 inhibition diminished acute lung injury in murine pneumococcal pneumonia

Critical care medicine, 2009-02, Vol.37 (2), p.584-590

2009

Volltextzugriff (PDF)

Prostanoid pattern and iNOS expression during chondrogenic differentiation of human mesenchymal stem cells

Journal of cellular biochemistry, 2006-07, Vol.98 (4), p.798-809

2006

Volltextzugriff (PDF)

In vitro differentiation of human monocytes to macrophages: change of PDE profile and its relationship to suppression of tumour necrosis factor‐α release by PDE inhibitors

British journal of pharmacology, 1997-05, Vol.121 (2), p.221-231

1997

Volltextzugriff (PDF)

PKCθ and PKA are antagonistic partners in the NF-AT transactivation pathway of primary mouse CD3+ T lymphocytes

Blood, 2006-06, Vol.107 (12), p.4841-4848

2006

Volltextzugriff (PDF)

1 – 25 von 71

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(61)
Mit Volltextzugriff
(57)

Publikationsform

Sprache

Englisch
(71)
Deutsch
(1)

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(46)
Science & Technology
(46)
Animals
(36)
Phosphodiesterase Inhibitors - Pharmacology
(25)
Biological And Medical Sciences
(24)
Humans
(23)
Pharmacology & Pharmacy
(20)
Male
(19)
Medical Sciences
(19)
Rats
(19)
Cells, Cultured
(14)
Pharmacology. Drug Treatments
(13)
In Vitro Techniques
(12)
Rolipram
(12)
Respiratory System
(11)
Dose-Response Relationship, Drug
(10)
Female
(9)
Biochemistry & Molecular Biology
(8)
Phosphoric Diester Hydrolases - Metabolism
(8)
Pyridazines - Pharmacology
(8)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

The preclinical pharmacology of roflumilast – A selective, oral phosphodiesterase 4 inhibitor in development for chronic obstructive pulmonary disease

cAMP Phosphodiesterase Inhibitors Increases Nitric Oxide Production by Modulating Dimethylarginine Dimethylaminohydrolases

Antiremodeling Effects of Iloprost and the Dual-Selective Phosphodiesterase 3/4 Inhibitor Tolafentrine in Chronic Experimental Pulmonary Hypertension

Phosphodiesterase 2 inhibition diminished acute lung injury in murine pneumococcal pneumonia

Inhaled tolafentrine reverses pulmonary vascular remodeling via inhibition of smooth muscle cell migration

Anti-inflammatory and immunomodulatory potential of the novel PDE4 inhibitor roflumilast in vitro

Phosphodiesterase Inhibitors

Effect of nitric oxide synthase (NOS) inhibition on macro- and microcirculation in a model of rat endotoxic shock

Effects of theophylline and rolipram on leukotriene C4 (LTC4) synthesis and chemotaxis of human eosinophils from normal and atopic subjects

Detection of reactive oxygen species in isolated, perfused lungs by electron spin resonance spectroscopy

Low-dose systemic phosphodiesterase inhibitors amplify the pulmonary vasodilatory response to inhaled prostacyclin in experimental pulmonary hypertension

Smokers with COPD Show a Shift in Energy and Nitrogen Metabolism at Rest and During Exercise

Phosphodiesterase profiles of highly purified human peripheral blood leukocyte populations from normal and atopic individuals: A comparative study

Subthreshold doses of specific phosphodiesterase type 3 and 4 inhibitors enhance the pulmonary vasodilatory response to nebulized prostacyclin with improvement in gas exchange

Characterization of the Phosphodiesterase (PDE) Pattern of in Vitro-Generated Human Dendritic Cells (DC) and the Influence of PDE Inhibitors on DC Function

Phosphodiesterase 1 upregulation in pulmonary arterial hypertension : Target for reverse-remodeling therapy

Protection from T cell-mediated murine liver failure by phosphodiesterase inhibitors

Tumor necrosis factor-α–dependent expression of phosphodiesterase 2: role in endothelial hyperpermeability

The specific type III and IV phosphodiesterase inhibitor zardaverine suppresses formation of tumor necrosis factor by macrophages

Phosphodiesterase inhibitors: history of pharmacology

Influence of selective phosphodiesterase inhibitors on human neutrophil functions and levels of cAMP and Cai

Phosphodiesterase 2 inhibition diminished acute lung injury in murine pneumococcal pneumonia

Prostanoid pattern and iNOS expression during chondrogenic differentiation of human mesenchymal stem cells

In vitro differentiation of human monocytes to macrophages: change of PDE profile and its relationship to suppression of tumour necrosis factor‐α release by PDE inhibitors

PKCθ and PKA are antagonistic partners in the NF-AT transactivation pathway of primary mouse CD3+ T lymphocytes

Suchergebnisse filtern